节点文献
沙美特罗替卡松气雾剂治疗支气管哮喘的临床有效性评析
The Clinical Effectiveness of Salmeterol Xinafoate and Fluticasone Propionate Aerosol in the Treatment of Bronchial Asthma
【摘要】 目的研究沙美特罗替卡松气雾剂治疗支气管哮喘的临床有效性。方法以2014年1月—2016年12月支气管哮喘患者100例随机分两组。A组采用丙酸氟替卡松治疗,B组在A组基础上用沙美特罗替卡松气雾剂治疗。比较两组患者支气管哮喘控制效果;不良反应发生情况;治疗前和治疗后患者第1 s用力呼气容积、血清ET-1水平、呼气峰流量的差异。结果 B组患者支气管哮喘控制效果高于A组,P<0.05;B组不良反应发生情况和A组比较差异无统计学意义,P>0.05;治疗前两组第1 s用力呼气容积、血清ET-1水平、呼气峰流量比较差异无统计学意义,P>0.05;治疗后B组第1 s用力呼气容积、血清ET-1水平、呼气峰流量改善幅度更大,P<0.05。结论沙美特罗替卡松气雾剂治疗支气管哮喘的临床有效性高,可有效改善患者肺功能和血清学指标,无明显副作用,安全有效。
【Abstract】 Objective To study the clinical efficacy of salmeterol in the treatment of bronchial asthma with aerosol. Methods From January 2014 to December 2016, 100 patients with bronchial asthma were randomly divided into two groups. Group A was treated with fluticasone propionate and group B was treated with salmeterol in the group A. The effects of bronchial asthma control, the level of serum ET-1, and the expiratory flow were compared between the two groups before and after treatment. ResultsB group of patients with bronchial asthma control is higher than that of A group, P < 0.05, the incidence of adverse reactions in group B and A group showed no significant difference, P > 0.05, the two groups before treatment, the first second forced expiratory volume, serum ET-1 level, peak expiratory flow showed no significant difference, P > 0.05, the first second forced expiratory volume, serum ET-1 level, peak expiratory flow improved more significantly, P < 0.05. Conclusion In the treatment of bronchial asthma clinical efficacy, can effectively improve the pulmonary function and serum index, no significant side effects, safe and effective.
【Key words】 salmeterol xinafoate and fluticasone propionate aerosol; bronchial asthma; pulmonary function; serological markers;
- 【文献出处】 中国继续医学教育 ,China Continuing Medical Education , 编辑部邮箱 ,2017年05期
- 【分类号】R562.25
- 【下载频次】22